Rydapt is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with acute myelogenous leukemia (AML) that has tested positive for the FLT3 mutation. Rydapt is also approved to treat mast cell leukemia. Rydapt may be referred to by its drug name, midostaurin.
Rydapt is used as targeted therapy for leukemia. Rydapt is a member of a class of drugs called kinase inhibitors. Rydapt is believed to work by inhibiting the proliferation of leukemia cells.
How do I take it?
Prescribing information states that Rydapt is taken orally twice daily.
Rydapt comes in capsule form.
The FDA-approved label for Rydapt lists common side effects including fatigue, headache, fever, cold or flu symptoms, nosebleeds, mouth sores, nausea, vomiting, diarrhea, abdominal pain, pain in muscles or bones, hyperglycemia (high blood glucose levels), edema (swelling), and petechiae (tiny red, brown, or purple dots on the skin caused by bleeding beneath the skin). People with implanted devices, such as a central line or catheter, may have a higher risk of device-related infection.
Rare but serious side effects listed for Rydapt include fetal harm in pregnant women and potentially fatal lung damage.
For more details about this treatment, visit:
Rydapt — Novartis
AML: Chemotherapy and Drug Therapy — Leukemia & Lymphoma Society